Achieving Rapid Door-To-Balloon Times
Opening the door to a new class of proteasome inhibitors
Amarin agreement opens off-label promotion door
Prognostic Implications of Door‐to‐Balloon Time and Onset‐to‐Door Time on Mortality in Patients With ST‐Segment–Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
TLR5 opens the door to neuropathic-pain treatment
F.S. details of cellar window and door frames : Sheet no. 4.
Opening the door to an epigenetic target
Cellar door - a strategic perspective
Closing the door on KRAS-mutant lung cancer
Opening the door to TB